Microenvironment of chronic lymphocytic leukaemia
Microenvironment of chronic lymphocytic leukaemia
Chronic lymphocytic leukaemia: Transition to a new era
Ibrutinib as a frontline therapy in RESONATE2 trials for CLL
The role of the microenvironment and novel therapies in CLL
Multi-target S-DNA increases colorectal cancer screening among previously non-compliant patients
p62: Metabolism and the tumour microenvironment
Cancer cells plasticity and drug resistance
Targeted therapy shows continued promise in patients whose tumours had NTRK gene fusions
Editor's Choice for April 2016
Drugging “undruggable” transcription factor drivers in cancer
Pembrolizumab yielded durable responses in patients with advanced Merkel cell carcinoma
Combination therapy before surgery improves outcomes for patients with HER2 positive breast cancer